Archbishop Stepinac High School, in White Plains, N.Y., is one of the first schools in the U.S. to do away with paper textbooks. Instead, the all-boys prep school requires students to use tablets and laptops in class. (Data provided by Statista.com.)
NYS Entity Status
NYS Filing Date
JANUARY 09, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2013 - J&J INSTALLERS CORPORATION
AROUND THE WEB
- A High School Without Textbooks
Tuesday Oct 8, 2013
- Hidden in Plain Sight: A Powerful Way to Beat the Market
Tuesday Jun 13, 2017
Few investors read corporate disclosures because they are boring and rarely change. But a strategy based on changes in the documents beats the market by 22 percentage points a year.
- biosimilar drugs can be a hard sell
By Jared S. Hopkins - Tuesday Aug 15, 2017
Part of the problem: a web of relationships between drug companies and insurers that shields incumbent drugs and often sidelines upstarts until the market becomes crowded.Pfizer said this month that Inflectra, its version of the blockbuster Johnson & Johnson rheumatoid arthritis drug Remicade, brought in $94 million in the second quarter.J&J spokeswoman Caroline Pavis said in a statement that Remicade is sold in a highly competitive market and that health plans decide on coverage.Doctors and patients tend to be loyal to innovative drugs that have worked well, payers are cautious in adopting alternatives, and Biosimilars can’t be swapped at the pharmacy because they aren’t identical to the drugs they are designed to replace.Remicade, known as infliximab and approved in the U.S. in 1998 for treating the digestive disorder Crohn’s disease, was cleared for rheumatoid arthritis a year later.J&J has exclusive contracts in nearly half its market, according to analyst Ronny Gal of Sanford Bernstein & Co., meaning payers agree to cover only Remicade for rheumatoid arthritis.When Sandoz released white-blood-cell booster Zarxio, the first biosimilar approved in the U.S., two years ago, it cost 15 percent less than Amgen’s Neupogen.[...] Neupogen has gradually lost its dominance, with sales sliding from $1.4 billion in 2013 to $765 million last year.[...] another similar drug, Granix by Teva Pharmaceutical, has been cleared, and Express Scripts last week became the second pharmacy-benefit manager to exclude Neupogen from its list of covered medicines.[...] Kay’s hospital found Inflectra cost $25 more than Remicade a vial, a discrepancy he attributes to pricing negotiations involving the supply chain.Makers of name-brand drugs once opposed biosimilars, citing safety among other concerns, but now say they have the manufacturing muscle and experience to produce and distribute the drugs.“For 20 years, until maybe this year, the brand industry’s position was, ‘Don’t take a biosimilar, it’s scary, it’s dangerous,’” said Bruce Leicher, senior vice president and general counsel at Momenta Pharmaceuticals, which sells generics and is developing Biosimilars.
- Phone Booths Are Back in Times Square. No Quarters Required.
By TAMARA BEST - Wednesday Jul 5, 2017
“Once Upon a Place,” an installation in which immigrants’ oral histories can be listened to by phone, touches on themes like belonging and displacement.
- Trump Accused Of Violating Constitution By Blocking Twitter Users
Wednesday Jun 7, 2017
"It is plain that our clients were blocked from your account on the basis of their viewpoints," the Knight First Amendment Institute says in a letter to the White House